Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1383&sort=-funder_divisions
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-funder_divisions", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1419&sort=-funder_divisions", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=-funder_divisions", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1382&sort=-funder_divisions" }, "data": [ { "type": "Grant", "id": "8709", "attributes": { "award_id": "1R43IP001168-01A1", "title": "Identification of Serodiagnostic Epitopes for SARS-CoV-2, endemic HCoV?s and influenza virus", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-30", "end_date": "2022-09-29", "award_amount": 243000, "principal_investigator": { "id": 24492, "first_name": "DAVID", "last_name": "CAMERINI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1738, "ror": "", "name": "IMMPORT THERAPEUTICS, INC.", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1738, "ror": "", "name": "IMMPORT THERAPEUTICS, INC.", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Identification of Serodiagnostic Epitopes for SARS-CoV-2, Endemic Human Coronaviruses and Influenza Virus A novel human coronavirus, which causes severe acute respiratory disease, now known as SARS- CoV-2 emerged in December 2019. Infection with SARS-CoV-2 spread rapidly worldwide and on 11 March 2020 it was declared a pandemic by the World Health Organization. As of 4 September 2020, there are over 26 million confirmed cases of coronavirus infectious disease (COVID-19) caused by this new virus, resulting in more than 870,000 deaths, corresponding to a mortality rate of ~3.3%, although the mortality rate varies widely from country to country and is subject to considerable uncertainty. Best current estimates indicate that SARS-CoV-2 has a basic reproductive number, R0, of 2 to 2.5 and an incubation time of approximately 4.6 days, which allow rapid spread of SARS-CoV-2. The USA has more cases of COVID-19 and more deaths from the disease than any other country. Since the beginning of this pandemic the scientific community came together in an unparalleled effort to advance diagnostic and vaccine development and despite all this effort and some of the success is it has brought we are still nowhere near the end of this pandemic. Although laboratory tests for the SARS-CoV-2 genome and antibodies have been developed, a reliable point-of care (POC) test for antibodies to SARS-CoV-2 and influenza virus that does not cross-react with endemic human coronaviruses (HCoV’s) is still urgently needed to guide clinical care as well as public health measures including opening schools, businesses and public gatherings. Given the impending influenza season it will be critical to have fast and specific test to distinguish between those three causes of respiratory infection with partially overlapping symptoms. We therefore seek an R43 grant to create a large protein and peptide microarray for identification of the best antigens and epitopes for sensitive and specific detection of serum antibodies reactive with SARS-CoV-2 and influenza virus. Next, we will create a sensitive and specific ELISA for antibodies to SARS-CoV-2 and will collaborate with others to create a rapid antibody assay suitable for use at the point of care. This will greatly facilitate public health and medical responses to the ongoing outbreak of COVID-19, seasonal influenza and for future waves of disease which may occur. We propose a novel approach to discovery of the best antigens or epitopes for sensitive and specific detection of infection by SARS-CoV-2 and influenza virus and for distinguishing antibodies to SARS-CoV-2 from antibodies to endemic HCoV’s. Our specific aims are: 1) add the major structural proteins of currently circulating influenza viruses, HCoV-229E and HCoV- HKU1, as well as peptides and fragments of these proteins to our existing coronavirus protein microarray, (2) develop and validate a diagnostic algorithm for distinguishing SARS-CoV-2 from infection by the four endemic HCoV’s and for detecting new influenza virus infection and (3) create and test prototype antibody ELISA’s for sensitive and specific detection of antibodies to SARS-CoV-2.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8712", "attributes": { "award_id": "1R43IP001164-01", "title": "Adjuvanted Recombinant Candidates to Prime / Boost COVID-19 RNA Vaccines", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-30", "end_date": "2022-09-29", "award_amount": 243000, "principal_investigator": { "id": 24497, "first_name": "DARRICK Albert", "last_name": "CARTER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1739, "ror": "", "name": "PAI LIFE SCIENCES, INC.", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1739, "ror": "", "name": "PAI LIFE SCIENCES, INC.", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in late 2019 causing Coronavirus Disease 2019 (COVID-19) and within months became a worldwide pandemic - as of the writing of this proposal, at least 82.5M people have been infected and more than 1.8M have died in addition to having a significant impact on the worldwide economy. Multiple vaccines are in development for COVID-19 and two of these have been awarded emergency use approval from the US FDA based on RNA platforms. With our partners at HDT Bio Corp. we are soon to enter phase I clinical trials with an RNA-based vaccine, HDT-301. While the development and deployment of these vaccines is exciting and has moved with unprecedented speed, it is unclear how durable the immune responses will be and whether or not they will induce broad protection against emerging strains. Therefore, the ability to boost these vaccines should be investigated to determine if a prime / boost regimen can be deployed in the face of waning immunity or newly emerging viral variants like the recently identified UK strain. As next generation candidates we are now producing 4 different adjuvants containing a non-GLA based TLR4 active ingredient derived from MPL referred to as 3D(6acyl)-PHAD (“3D-PHAD”). These adjuvants are called AlT4™, EmT4™, LiT4™, and MiT4. In this proposal, we will test each of these adjuvants in combination with recombinant Covid-19 spike protein in mice as adjuvanted protein vaccines and as RNA vaccine boosters. Following immunization with protein / adjuvant, potential protection against multiple Covid-19 spike protein variants will be confirmed using both ELISA and viral neutralization assays. Lead combinations will then be tested using a prime-boost strategy using a proprietary mRNA prime vaccination with HDT-301 followed by a adjuvanted protein boost. Specifically, we propose to (1) Down-select a lead adjuvant in mice and (2) Determine protection from Covid-19 using an RNA prime protein boost immunization strategy. When this research is completed, we will have protocols and data supporting the use of these vaccines in further studies in higher animal models leading to human trials as the data warrant.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8720", "attributes": { "award_id": "6U01IP001160-01M003", "title": "Collaborative Research on Influenza, Coronavirus Disease 2019 (COVID-19), and Other Respiratory Pathogens in South Africa", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-01", "end_date": "2024-08-31", "award_amount": 175000, "principal_investigator": { "id": 24504, "first_name": "Cheryl", "last_name": "Cohen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1742, "ror": "https://ror.org/00znvbk37", "name": "National Health Laboratory Service", "address": "", "city": "", "state": "", "zip": "", "country": "SOUTH AFRICA", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1742, "ror": "https://ror.org/00znvbk37", "name": "National Health Laboratory Service", "address": "", "city": "", "state": "", "zip": "", "country": "SOUTH AFRICA", "approved": true }, "abstract": null, "keywords": [], "approved": true } }, { "type": "Grant", "id": "8721", "attributes": { "award_id": "1U01IP001160-01", "title": "Collaborative Research on Influenza, Coronavirus Disease 2019 (COVID-19), and Other Respiratory Pathogens in South Africa", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-01", "end_date": "2026-08-31", "award_amount": 1100000, "principal_investigator": { "id": 24504, "first_name": "Cheryl", "last_name": "Cohen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1742, "ror": "https://ror.org/00znvbk37", "name": "National Health Laboratory Service", "address": "", "city": "", "state": "", "zip": "", "country": "SOUTH AFRICA", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1742, "ror": "https://ror.org/00znvbk37", "name": "National Health Laboratory Service", "address": "", "city": "", "state": "", "zip": "", "country": "SOUTH AFRICA", "approved": true }, "abstract": "This project aims to generate a body of data that will assist in formulating appropriate policies for the reduction of morbidity and mortality associated with influenza Coronavirus 2019 (COVID-19) and other respiratory pathogens in South Africa. Specifically we aim to perform influenza virus hemagglutination inhibition (HI) testing of serum samples already collected from PHIRST-C participants in a rural and an urban site and from HUTS participants in 2 key communities before and after the 2021 influenza season to determine rates of recent influenza infection. We also aim to characterize healthcare seeking behavior for respiratory illness during the influenza season in the year following the South African COVID-19 epidemic first and second waves through a survey conducted following the influenza season and compare healthcare seeking behavior for respiratory illness to a survey conducted before the 2021 influenza season and assess the impact of different factors on healthcare seeking behavior. We aim to describe the prevalence of MTB-SARS-CoV-2 coinfection and the impact of coinfection on clinical presentation and outcomes in patients presenting with ILI or suspected COVID-19 at ILI surveillance sites or patients admitted with SRI at pneumonia surveillance sites in South Africa. We aim to pilot the implementation of laboratory-confirmed influenza surveillance among individuals participating to the CoughWatchSA participatory digital surveillance platform, compare influenza virus circulation as detected in facility-based surveillance and through the CoughWatchSA platform and to evaluate concordance between self-reported ARI on the CoughWatchSA platform and laboratory-confirmed infection with influenza. This will be achieved through testing of collected serum samples for the presence of anti-influenza antibodies using HI assay, performing a survey of healthcare utilization and serosurvey at two sites in South Africa and implementation of systematic Mycobacterium tuberculosis testing of all participants enrolled in existing pneumonia and influenza-like illness surveillance programmes. Lastly we will pilot self- swabbing of individuals participating in the Coughwatch app for syndromic influenza surveillance.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8726", "attributes": { "award_id": "1U01FD007452-01", "title": "Ga. Dept. of Agriculture - NARMS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24507, "first_name": "Claudine", "last_name": "Kabera", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-01", "end_date": "2025-08-31", "award_amount": 182000, "principal_investigator": { "id": 24508, "first_name": "Carrie", "last_name": "Crabtree", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1743, "ror": "", "name": "GEORGIA STATE DEPARTMENT OF AGRICULTURE", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1743, "ror": "", "name": "GEORGIA STATE DEPARTMENT OF AGRICULTURE", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "NARMS - Project Summary/Abstract The Georgia Department of Agriculture (GDA) is the state agency responsible for regulation of food manufactured facilities and retail establishments. GDA Laboratories (Lab) are the primary servicing laboratories for the regulatory programs and are focused on food analysis for chemical and microbiological contaminants. Since 2011, GDA has pursued FDA grants and cooperative agreements to improve and harmonize our state regulatory and testing capability. Through these grants the Lab achieved accreditation to ISO 17025 international standards which allows our regulatory agencies to perform contractual work on behalf of FDA. Since GDA is Georgia’s regulatory authority over food retail establishments, the agency has inspectors positioned all throughout The State of Georgia. These inspectors are trained to collect samples and return them to our lab for testing that can support regulatory enforcement. Since GDA already has infrastructure designated for sample collection at retail establishments and the analysis of microorganisms by the Lab, this award opportunity NARMS (National Antimicrobial Resistance Monitory System) should make a good fit to be implemented by GDA. The Georgia Department of Public Health (GDPH) Laboratory is currently awarded this grant but has contacted GDA to request assistance or taking it over since the COVID 19 pandemic has become their top priority. In summary, GDA inspectors will collect the samples and send them to the Lab per routine protocols. The Lab will screen the samples for the target organisms suggested in the Funding Opportunity Award (FOA). The Lab will utilize methods described in the project protocol in addition to screening by approved and validated ELISA or PCR platforms. Isolates showing typical characteristics will be further examined and confirmed or sent to FDA for further evaluation. As needed, GDPH has agreed to also assist in in Whole Genome Sequencing of the isolates, since GDA does not currently have that ability, in addition to mentoring of the methods and program until fully established. The Lab has developed and demonstrated successful relationships with their regulatory partners and the GDPH Lab, which should indicate its ability to fulfill this objective. The Lab also routinely performs thousands of microbiological analyses on retail food samples annually. If awarded, GDA will be capable of enhancing and strengthening antimicrobial resistance surveillance data. This in turn can be used to inform public health stakeholders about populations of resistant strains and if current policy and practices are adequate for overall safety of consumers.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8737", "attributes": { "award_id": "1U19OH012297-01", "title": "Johns Hopkins P.O.E. Total Worker Health Center in Mental Health (POE Center)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24486, "first_name": "Maria", "last_name": "Lioce", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-01", "end_date": "2026-08-31", "award_amount": 1399623, "principal_investigator": { "id": 24525, "first_name": "Meghan F.", "last_name": "Davis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 24222, "first_name": "M Daniele", "last_name": "Fallin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "The overarching goal of the proposed Johns Hopkins P.O.E. Total Worker Health Center in Mental Health (POE Center) is to promote worker mental health and well-being through research, education, outreach and evaluation activities that integrate the psychosocial, organizational, and environmental contexts of worker health. Given the rapid evolution of who works, how they work, and where they work— changes that have accelerated given employer and governmental response to the COVID-19 pandemic—the workforce and workplace are being transformed in ways that will have lasting consequences post-pandemic. Since a large proportion of human life is spent at work, workplace exposures (including psychosocial) are an important contribution to population health or illness. This supports the critical need to not only identify how large-scale disruptions like the COVID-19 pandemic will modify the workforce and workplace in relation to worker mental health, substance use and well-being outcomes, but also to identify and empower resilient systems for health protection and health promotion to maintain workforce functions, health, and well-being before, during and after crises. We will address the following aims: 1) To create a NIOSH Total Worker Health® center that serves the National Occupational Research Agenda (NORA) in Total Worker Health® (TWH) with intentional focus and resources on mental health and substance use prevention and treatment among workers; 2) Integrate concepts of psychosocial, personal, organizational, and environmental context into TWH monitoring and evaluation; and 3) To evaluate POE Center activities in outreach, training, dissemination, and research, and to support the overall goals of the POE Center and NIOSH TWH program. Given the special issues related to mental and behavioral health, including the alarming frequency of problems, the very real barriers due to stigma and privacy concerns, and the hidden costs due to presenteeism versus absenteeism, a NIOSH Total Worker Health center specifically dedicated to worker mental health is greatly needed.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8747", "attributes": { "award_id": "1R43IP001169-01A1", "title": "Rapid mass production of human influenza vaccine in insects using genome editing", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-30", "end_date": "2022-09-29", "award_amount": 243000, "principal_investigator": { "id": 24538, "first_name": "Virginia", "last_name": "Emery", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1747, "ror": "", "name": "BETA HATCH INC.", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1747, "ror": "", "name": "BETA HATCH INC.", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "As the recent COVID-19 pandemic has made clear, the rapid mass production of vaccines for emerging infectious diseases is of paramount importance. The use of the baculovirus/insect cell expression system for in vitro protein expression has been a game changer for vaccine production, but it also introduces challenges: transfection can be difficult, needs to be repeated with every batch, and the final product requires multiple purification steps to remove the residual baculovirus. We propose an alternative approach that could side-step the drawbacks associated with baculovirus/insect cell expression system: in vivo vaccine production in a scalable insect non-mammalian genetic model system. We aim to achieve this by using the CRISPR-Cas9 system to insert viral antigen genes for human and avian influenza into insects that are already mass produced for feed and/or waste management. Both the yellow mealworm (Tenebrio molitor) and the blow fly (Phormia regina) are promising bioreactors for manipulating protein expression in vivo due to their high metabolism and fecundity, ease of rearing, high resilience, and versatility in mass production systems (large-scale production facilities already exist for both insects). Unlike existing transgenic insect hosts such as cabbage looper larvae, both mealworms and blowflies are gregarious and can be cost effectively mass-reared at a scale of several tons per day. By using the CRISPR-Cas9 technique for recombinant protein expression to express influenza antigens in these insects, we will engineer life-stage dependent activation of the antigen production. Using existing technologies to facilitate rapid antigen protein purification, we will confirm the antigen production and characterize it. Finally, we will quantify what impact (if any) the modified genome has on phenotypes relevant to mass production and validate cost considerations for production. This work will set the stage for a steady supply of low-cost and customizable antigens, using insect biomass as an affordable and scalable bioreactor.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8749", "attributes": { "award_id": "1U01IP001157-01", "title": "IP21-002, Enhanced Surveillance to Assess Vaccine Preventable Enteric and Respiratory Virus Illnesses", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-01", "end_date": "2026-08-31", "award_amount": 1441645, "principal_investigator": { "id": 24541, "first_name": "JANET A", "last_name": "ENGLUND", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 732, "ror": "https://ror.org/01njes783", "name": "Seattle Children's Hospital", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 24542, "first_name": "Eileen", "last_name": "Klein", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 732, "ror": "https://ror.org/01njes783", "name": "Seattle Children's Hospital", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "We will conduct active, prospective inpatient, emergency department (ED) and asymptomatic healthy control (HC) surveillance in children at SCH and affiliated clinics in the Seattle metropolitan area. We will enroll subjects to describe the population-based burden of AGE and ARI in King County and Snohomish County, WA and evaluate effectiveness of licensed vaccines, such as influenza (Flu) and rotavirus (RV) vaccine (vx). We will assess the epidemiology and natural history of pediatric respiratory and enteric viral diseases and assess transmission dynamics for vx-preventable (RV, Flu) and potentially vx-preventable pathogens, such as norovirus (NV), respiratory syncytial virus (RSV), and SARS-CoV-2. After obtaining informed consent and assent, if applicable, in English or Spanish, we will interview families to collect epidemiological and clinical information, vaccine history, and obtain study specimens including respiratory and/or stool specimens, depending on clinical symptoms. Vaccination data are recorded in our state vaccine database, which is very reliable and complete. During times of COVID-19, novel methods of enrollment and capturing data may be utilized as per IRB- approved protocols including verbal or online consent, telephone interviews to complete data capture, and home specimen collection. Respiratory specimens and stool samples will be tested for multiple respiratory and enteric pathogens using sensitive and specific molecular PCR tests in laboratories using approved testing strategies that have been validated by proficiency testing. With this information, in addition to publicly available state-wide data describing inpatient and acute care visits in WA, we will obtain incidence rates of ED and inpatient visits and characterization of illness for multiple viral pathogens, including those responsible for vx- preventable disease and potentially vx-preventable disease, and others related to acute respiratory and enteric diseases, such as rhinovirus, EVD-68, parainfluenza viruses, adenoviruses, and human metapneumovirus. Additionally, we will continue ongoing surveillance for Acute Flaccid Myelitis (AFM) throughout WA state. In collaboration with statewide AFM expert and SCH neurologist, Dr. Catherine Otten and using WA DOH surveillance data we will conduct active surveillance, establish incidence rates, and compare rates of AFM to current circulation of respiratory and gastrointestinal infections. We will characterize the clinical spectrum of AFM by evaluating clinical and laboratory data, MRI findings, therapeutic interventions, and outcomes to inform early diagnosis, prognosis, prevention, and treatment.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8752", "attributes": { "award_id": "1R01HS027970-01A1", "title": "The Medicaid expansion in the age of COVID-19: Effects on coverage, access, use, financial stress, and health.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24040, "first_name": "Fred", "last_name": "Hellinger", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-30", "end_date": "2025-08-31", "award_amount": 386223, "principal_investigator": { "id": 24545, "first_name": "JOSE JULIO", "last_name": "ESCARCE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic has posed an unprecedented threat to the health and well-being of Americans, especially low-income and minority Americans and those in poor health or who lost jobs in the economic downturn. The proposed project will examine the protective effect of access to affordable health insurance for poor and low-income Americans in the setting of major health, economic, and social disruptions to their lives. Access to affordable health insurance differs across states because only 35 states and the District of Columbia have adopted the Medicaid expansion to all working-age adults with incomes below 138% of poverty permitted under the Affordable Care Act. The proposed project has three Specific Aims: Aim 1. To assess the protective effects of the Medicaid expansion on insurance coverage for adults and children following the onset of the COVID-19 pandemic. Aim 2. To assess the protective effects of the Medicaid expansion on access to and use of health care, health care expenditures, and financial stress following the onset of the COVID-19 pandemic. Aim 3. To assess the protective effects of the Medicaid expansion on health outcomes, including physical and mental health, for adults and children following the onset of the COVID-19 pandemic. We will also assess how the protective effects differ for disadvantaged persons including poor and low- income persons, African Americans and Hispanics, persons in poor health, and persons who lose their jobs. We will employ two complementary national surveys—the National Health Interview Survey (NHIS) and the Medical Expenditure Panel Survey (MEPS)—in a phased analysis of data straddling the onset of the pandemic. NHIS covers numerous outcomes, with especially detailed measures of financial stress, children's mental health, and some health behaviors. MEPS has more detailed measures of adults' mental health and health care use and expenditures, and its panel design enables us to use analytic methods that more comprehensively control for subjects' characteristics. However, MEPS data are not available until later. We will use regression analysis to model the study outcomes as functions of individual characteristics; baseline state characteristics; time-varying local area characteristics including pandemic severity, depth of the economic downturn, state policies intended to slow spread of the pandemic, and adherence to social distancing; and interactions between states' Medicaid expansion status and local area characteristics. Our approach will enable us to quantify the protective effects of the Medicaid expansion on the study outcomes and assess the main pathways through which these effects occur. The proposed project will assess the value of access to affordable health insurance for poor and low-income persons during the COVID-19 pandemic, but its lessons will be generalizable to other recessions and public health crises, natural and man-made disasters, and people who experience health or economic setbacks in normal times.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8759", "attributes": { "award_id": "1R21HS028563-01", "title": "An EHR-Based Screening Tool to Support Safe Discharges of COVID-19 Patients in the Emergency Department", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24555, "first_name": "Mario", "last_name": "Teran", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-30", "end_date": "2023-03-31", "award_amount": 299449, "principal_investigator": { "id": 24556, "first_name": "Jessica E", "last_name": "Galarraga", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1515, "ror": "", "name": "MEDSTAR HEALTH RESEARCH INSTITUTE", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1515, "ror": "", "name": "MEDSTAR HEALTH RESEARCH INSTITUTE", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "The proposed study will develop a screening tool using electronic health record data that predicts the risk of ED return and associated morbidity or mortality to support safe and appropriate dispositions in the ED for patients with the novel coronavirus disease-2019 (COVID-19). Due to the challenges of COVID-19, with highly variable symptoms, the paucity of existing research, and strains on ED capacity, emergency clinicians must make rapid clinical decisions with limited information. Moreover, in the ED, patients often present for evaluation early on during the course of their illness, which is when the clinical trajectory for COVID-19 is most volatile and the risk for subsequent decompensation is highest. Using predictive modeling with natural language processing (NLP) and machine learning (ML) techniques can leverage the data-rich environment of the ED to improve the quality of care delivered to patients with COVID-19. This study directly addresses priorities highlighted in PA-17-246 by bringing research evidence to clinical practice through the development and evaluation a health IT solution that combines the use of NLP with a decision support tool to turn unstructured clinical data into knowledge that can be applied to practice. Developing and operationalizing the proposed COVID-19 ED return screening tool (CERST) can help ED clinicians avoid premature discharges and engage in evidence-based discussions with COVID-19 patients regarding discharge plans. It may also reduce strain on hospital capacity by identifying patients safe for discharge and reserving resources for higher-risk COVID-19 patients. The project will be executed by a multidisciplinary team with expertise in emergency care, quality outcomes research, care transitions, and applying data science to improve clinical care, including ML and NLP methods. It will also use innovative methods, including a mixed methods approach to iteratively develop the concept map that will inform the predictive model. Moreover, the proposed project is designed to optimize the generalizability of CERST, by using a large, diverse study population, including data from a second health system with a different EHR using Fast Health Interoperability Resources (FHIR) specifications to assist with model interoperability. This will help optimize model performance for differing patient populations, health systems, and EHR platforms. Since the primary data source for this study is readily accessible to the study team, who possesses prior experience working with the data sources and performing the analytic procedures outlined in the proposal, the team is well-positioned to execute this study with timely dissemination of project findings.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1383, "pages": 1419, "count": 14184 } } }